661 results on '"Langer, Anatoly"'
Search Results
2. Cardiovascular risk factor management in patients with diabetes: Does management differ with disease duration?
3. Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement
4. Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation
5. Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI)
6. Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey
7. Insights Into the Current Management of Older Adults With Type 2 Diabetes in the Ontario Primary Care Setting
8. Guidelines Oriented Approach to Lipid (GOAL) Lowering Quality Improvement International Program
9. Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation: From the Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation (FREEDOM AF) and Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation (CONNECT AF)
10. Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations
11. The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients
12. Prognostic significance of low QRS voltage on the admission electrocardiogram in acute coronary syndromes
13. Type 2 Diabetes Mellitus Management in Canada: Is It Improving?
14. Use of a Treatment Optimization Algorithm Involving Statin-Ezetimibe Combination Aids in Achievement of Guideline-Based Low-Density Lipoprotein Targets in Patients With Dyslipidemia at High Vascular Risk Guideline-Based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC)
15. Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non–ST-elevation acute coronary syndromes
16. Obesity in patients with non-ST-segment elevation acute coronary syndromes: Results from the SYNERGY trial
17. Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS)
18. Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada
19. Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: The CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study
20. Comparison of Baseline Characteristics, Management and Outcome of Patients With Non–ST-Segment Elevation Acute Coronary Syndrome in Versus Not in Clinical Trials
21. Relation Between Hemoglobin Level and Recurrent Myocardial Ischemia in Acute Coronary Syndromes Detected by Continuous Electrocardiographic Monitoring
22. Relation Between Obesity and the Attainment of Optimal Blood Pressure and Lipid Targets in High Vascular Risk Outpatients
23. Usefulness of Statin–Ezetimibe Combination to Reduce the Care Gap in Dyslipidemia Management in Patients With a High Risk of Atherosclerotic Disease
24. Influence of Age on Use of Cardiac Catheterization and Associated Outcomes in Patients With Non-ST-Elevation Acute Coronary Syndromes
25. Treatment Inertia in Patients With Familial Hypercholesterolemia
26. Detection of atrial fibrillation in asymptomatic at-risk individuals
27. Risk factors and outcome of in-hospital ischemic stroke in patients with non-ST elevation acute coronary syndromes
28. Ischemic stroke: A cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial
29. How many cardiovascular events can be prevented with optimal management of high-risk Canadians?
30. Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: Resolved and unresolved issues
31. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk
32. Discordance Between Physicians' Estimation of Patient Cardiovascular Risk and Use of Evidence-Based Medical Therapy
33. Clinical implications of a next-day follow-up electrocardiogram in patients with non-ST elevation acute coronary syndromes
34. Bleeding and outcome in acute coronary syndrome: Insights from continuous electrocardiogram monitoring in the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial
35. Impact of delayed presentation on management and outcome of non–ST-elevation acute coronary syndromes
36. Smoking status and antithrombin therapy in patients with non–ST-segment elevation acute coronary syndrome
37. Quantitative troponin elevation does not provide incremental prognostic value beyond comprehensive risk stratification in patients with non–ST-segment elevation acute coronary syndromes
38. Routine early angioplasty after fibrinolysis for acute myocardial infarction
39. Is Treatment Inertia Unique to Publicly Funded Healthcare? Insights from the Guidelines Oriented Approach to Lipid lowering (GOAL) Canada Program
40. Prediction of One-Year Survival in High-Risk Patients with Acute Coronary Syndromes: Results from the SYNERGY Trial
41. Optimal medical therapy at discharge in patients with acute coronary syndromes: Temporal changes, characteristics, and 1-year outcome
42. Bedtime Administration of Graded-Release Diltiazem in Patients with Inadequate BP Control: A Tolerability and Efficacy Study
43. Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndrome
44. Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: An international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II
45. Missed opportunities for the secondary prevention of cardiovascular disease in Canada
46. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration
47. An Academic ECG Core Lab Perspective of the FDA Initiative for Digital ECG Capture and Data Management in Large-Scale Clinical Trials
48. Underuse of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes
49. The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: The GUSTO-IIb ECG Core Laboratory experience
50. ST-segment depression in non-ST elevation acute coronary syndromes: quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.